Orphalan's Acquisition of Orphelia Pharma: A Leap Forward in Rare Disease Treatment Orphalan's acquisition of Orphelia Pharma enhances its commitment to innovative treatments for rare diseases, particularly in pediatrics.

Orphalan's Acquisition of Orphelia Pharma: A Leap Forward in Rare Disease Treatment #Paris #France #Rare_Diseases #Orphalan #Orphelia

Orphalan Makes History as First European Firm to Launch Wilson's Disease Drug in China Orphalan has achieved a groundbreaking feat by becoming the first European company to launch its Wilson's disease treatment in China. This marks a significant advancement in rare disease care.

Orphalan Makes History as First European Firm to Launch Wilson's Disease Drug in China #China #Shanghai #Orphalan #Wilson_Disease #Ke_Pei_Ou